The Indian Journal of Sexually Transmitted Diseases and AIDS, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, serves as a vital platform for disseminating research and knowledge in the fields of sexually transmitted infections and HIV/AIDS management. With ISSN 2589-0557 and E-ISSN 2589-0565, this journal aims to bridge the gap in public health and clinical research by providing peer-reviewed articles that cover a range of topics from epidemiology to therapeutic advancements. Despite its status with an impact factor in the lower quartiles across relevant categories, including Q3 in Dermatology, Q4 in Infectious Diseases, and Q4 in Public Health, it holds potential for growth and greater visibility within the academic community. The journal's scope spans critical insights and innovative approaches in managing sexually transmitted diseases, and it is committed to fostering scholarly discourse among its readership consisting of researchers, health professionals, and students alike. As it converges from 2018 to 2024, the Indian Journal of Sexually Transmitted Diseases and AIDS continues to underscore the importance of addressing pressing health issues in India and beyond, while offering an accessible resource for those dedicated to this vital field.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

AJAR - African Journal of AIDS Research, an esteemed publication by Taylor & Francis Ltd, stands at the forefront of research in the field of HIV/AIDS, with a specific focus on the African continent. Established in 2003 and publishing continuously through 2024, this journal serves as a crucial platform for disseminating innovative research findings aimed at addressing the challenges of HIV/AIDS. With its ISSN 1608-5906 and E-ISSN 1727-9445, AJAR is indexed in prominent databases and holds a respectable Q3 rating in major categories such as Infectious Diseases, Medicine, Public Health, and Virology as of 2023. This positions the journal as a relevant resource for scholars and medical professionals looking to stay informed on the latest developments and strategies in AIDS research. Although it is not currently an open-access journal, AJAR provides readers with valuable insights that are essential for advancing public health initiatives and infectious disease research across Africa and beyond. The journal's commitment to high-quality peer-reviewed research underscores its importance within its field, making it a vital resource for researchers, students, and policymakers alike.

The Lancet HIV, published by Elsevier Inc in the United Kingdom, stands at the forefront of HIV research and public health, providing a vital platform for the dissemination of innovative findings and critical knowledge in the fields of epidemiology, immunology, infectious diseases, and virology. With its prestigious Q1 rankings in the aforementioned categories for 2023, the journal is recognized for its significant contribution to advancing understanding and addressing challenges posed by HIV globally. Its impressive standing, including a Scopus ranking in the 94th percentile for multiple categories, underscores its impact within the research community. The Lancet HIV publishes rigorously peer-reviewed research articles, reviews, and opinion pieces, ensuring that all stakeholders—researchers, practitioners, and policymakers—are engaged with up-to-date, evidence-based perspectives. Researchers and students alike will find this journal an invaluable resource for enhancing their knowledge and contributing to the ongoing discourse surrounding HIV treatment and prevention.

AIDS REVIEWS, published by Permanyer Publishing, is a distinguished academic journal dedicated to providing comprehensive insights into the field of AIDS research. Since its inception in 2000, the journal has served as a vital platform for disseminating knowledge on various aspects of HIV/AIDS, including prevention, treatment advancements, and socio-medical implications. With a commendable Q3 ranking in both Infectious Diseases and Medicine (miscellaneous), as well as Pharmacology (medical) in 2023, the journal has made significant strides in the academic community, covering relevant topics and emerging trends up to 2024. Although not open access, AIDS REVIEWS continues to attract contributions from leading researchers and professionals, fostering a collaborative environment aimed at improving health outcomes related to AIDS. Located in Barcelona, Spain, this journal is an essential resource for anyone dedicated to advancing their understanding of this global health challenge.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, published by AOSIS, stands as a vital resource in the field of Infectious Diseases, particularly focusing on HIV medicine. With an ISSN of 1608-9693 and E-ISSN 2078-6751, this Open Access journal has been dedicated to disseminating cutting-edge research since 2001, ensuring that findings are accessible to a global audience of researchers, healthcare professionals, and students. Operating out of South Africa, the journal has earned a position in the Q3 quartile for Infectious Diseases, reflecting its commitment to advancing the understanding and treatment of HIV-related issues. Its Scopus ranking, presently at #207 out of 344, further emphasizes its scholarly influence, positioning it as an essential publication within the medical community. The journal aims to foster collaboration and innovation in HIV research and practice, bridging gaps between theory and real-world application to improve health outcomes in southern Africa and beyond.

Welcome to AIDS PATIENT CARE AND STDS, a leading journal dedicated to the comprehensive exploration of clinical practices, research advancements, and public health strategies centered around HIV/AIDS and sexually transmitted diseases. Published by Mary Ann Liebert, Inc., this esteemed journal has been at the forefront of disseminating critical findings since 1996, contributing to a robust understanding of the complexities surrounding these global health issues. With an impressive impact factor reflected in its 2023 Q1 quartile rankings in both Infectious Diseases and Public Health, Environmental and Occupational Health, the journal stands out among its peers, ranking at the 95th percentile for Public Health and 91st percentile in Infectious Diseases. Researchers, healthcare professionals, and students will benefit from its rich content, comprehensive studies, and critical reviews that aim to improve care practices and health outcomes. With a clear commitment to fostering knowledge and collaboration in the field, AIDS PATIENT CARE AND STDS is an essential resource for those dedicated to combating these pressing health challenges.

AIDS, published by Lippincott Williams & Wilkins, stands as a premier journal within the fields of immunology and infectious diseases, reflecting a distinguished history since its inception in 1987 and offering insights that shape contemporary research and practice. With an impressive impact factor and categorized in the Q1 quartile across critical areas including Immunology, Infectious Diseases, and Immunology and Allergy, the journal showcases high-quality, peer-reviewed articles that consistently contribute to the advancement of knowledge and innovation in the fight against AIDS and related conditions. Researchers and professionals will find its content invaluable, as it brings forth groundbreaking studies, novel therapeutic approaches, and comprehensive reviews that inform both clinical practices and public health policies. Although not an open access journal, it remains a vital resource for those committed to addressing one of the most pressing global health challenges of our time.

The Journal of the International AIDS Society, published by John Wiley & Sons Ltd, stands as a premier platform for advancing knowledge in the realms of infectious diseases and public health, boasting a strong Q1 ranking in both categories as of 2023. With its open-access format established since 2004, the journal ensures that groundbreaking research on HIV/AIDS and related issues is widely disseminated and easily accessible to a global audience. This commitment to accessibility significantly enhances its impact factor, making it a vital resource for researchers, practitioners, and students alike who are dedicated to improving health outcomes and understanding the complexities of the epidemic. Covering a diverse range of topics from prevention strategies to health policy, the journal supports its readers in staying at the forefront of public health discourse. With its base in the United States and an impressive Scopus ranking placing it within the top tiers of medical publications, the Journal of the International AIDS Society continues to foster collaboration and innovation in the fight against HIV/AIDS.

Virology, published by Academic Press Inc. Elsevier Science, is a prominent journal dedicated to advancing the knowledge and understanding of viral biology and pathogenesis since its inception in 1955. With a distinguished impact factor and recognized as a Q2 journal in the field of Virology for 2023, it ranks 38 out of 80 in the Scopus database for Immunology and Microbiology, placing it in the 53rd percentile among similar publications. This esteemed journal provides a platform for groundbreaking research, critical reviews, and comprehensive studies that contribute to our global understanding of viruses and their impact on health and disease. Although currently not an open-access journal, it remains accessible to a wide audience of researchers, professionals, and students who are keen to explore the latest advancements in virological research. The journal's scope encompasses a diverse range of topics, ensuring that it serves as an essential resource for anyone engaged in virology and related biomedical fields.